CROWN
2020
Lorlatinib in Untreated ALK-Positive Advanced NSCLC
In 296 patients with untreated advanced ALK-positive NSCLC, lorlatinib improved progression-free survival and intracranial response compared with crizotinib.
Result
Efficacy: BICR-assessed PFSHR 0.28 (95% CI 0.19-0.41) · P < 0.001
Below 1 favours lorlatinib, above 1 favours crizotinib.
- Absolute difference
- 39 points
- NNT
- 3
Absolute difference and NNT are derived from the event rates.
Also reported: Intracranial ORR 82% vs 23% in patients with measurable baseline brain mets.
- Subtopic
- ALK-rearranged NSCLC
- Design
- Open-label RCT
- Relevance
- Important: one of several pillars.
- Source
- Shaw AT, et al. N Engl J Med. 2020;383(21):2018-2029; Solomon BJ, et al. J Clin Oncol. 2024;42(29):3400-3409.doi 10.1056/NEJMoa2027187
Discussion & critique
Largest PFS effect ever reported in 1L ALK+ NSCLC; intracranial activity is the new benchmark.